QUIMIOTERAPIA DE INDUCCION EN TUMORES DE ......QUIMIOTERAPIA DE INDUCCION EN TUMORES DE CABEZA Y...
Transcript of QUIMIOTERAPIA DE INDUCCION EN TUMORES DE ......QUIMIOTERAPIA DE INDUCCION EN TUMORES DE CABEZA Y...
QUIMIOTERAPIA DE INDUCCION EN TUMORES
DE CABEZA Y CUELLO
¿TODAVIA EN DISCUSION?
Ricardo Hitt CENTRO INTEGRAL ONCOLOGIA CIOCC. MADRID
SEOM , SALAMANCA 2013
Ricardo Hitt 1
DISEÑO ENSAYOS CLINICOS
• Ensayos Fases II: en ocasiones demuestran una
evidencia de beneficio en los pacientes tratados
llegando a ser un tratamiento estándar sin estudios
de confirmación. Ejemplos: MOPP enf Hodgkin,
Glevec en Gist, BEP tumores germinales.
• Suelen ser estudios con población seleccionada y
en centros de referencia
Ricardo Hitt 2
DISEÑO ENSAYOS
• ENSAYOS FASES III : cuales son los
objetivos actualmente?
• Incremento supervivencia: la mayoría de las
enfermedades se tratan en 2º, 3º, ó 4º líneas
• Tiempo a la progresión: aplicable en tumores
metastásicos
• Intervalo libre de enfermedad: mas real cuando se
valora la Remisión Completa
• Preservación de órganos: válido solo en
enfermedades resecables y CURABLES con cirugía.
Ricardo Hitt 3
DISEÑO ENSAYOS CLINICOS
• META ANÁLISIS: que nivel de evidencia se puede
tener en poblaciones heterogéneas ?
• En puntuales MA se mezclan estudios diseñados
para diferentes enfermedades, con pronósticos
diferentes, localizaciones diversas, tratamientos
dispares y conclusiones que difieren de las
observadas en la práctica clínica. Ejemplo: MACH
(Pignon), incluye: tumores resecables, irresecables,
Laringe, Orofaringe, Cavidad Oral, Platinos, Platinos
subóptimos, No Platinos, diferentes técnicas y dosis
de Radioterapia, etc
Ricardo Hitt 4
DISEÑO ENSAYOS CLINICOS
• En Tumores de Cabeza y Cuello
(TCC) que esta demostrado?: • Ensayos Fases II: beneficios de la inducción en
centros y población seleccionada, Ejemplos: PPF ,
TPF + QTRT, se consiguen mejores resultados en las
diferentes supervivencias. Desventajas : en
ocasiones datos no reproducibles , requiere una
amplia experiencia y un importante manejo de
soporte.
Ricardo Hitt 5
DISEÑO ENSAYOS CLINICOS
• ENSAYOS FASES III : datos concluyentes • Tumores Resecables : EORTC , VETERANOS: la
quimioterapia de Inducción seguida de Rt permite reemplazar a la cirugía en tumores de laringe e hipofaringe, logrando semejante supervivencia pero con preservación de órganos.
• ECOG Forastiere: QTI , RT, QTRT demuestran igual supervivencia global pero mejor tasa de preservación de laringe con QTRT y QTI. A 10 años mejoría de ILE con QTI
Ricardo Hitt 6
DISEÑO ENSAYOS CLINICOS
• ENSAYOS FASES III : datos concluyentes
• Esquemas de inducción con Taxanos superior a PF
clásico. Ejemplos :
• PPF vs PF seguido QTRT estándar (Hitt et al JCO 2005)
• TPF vs PF seguido de QTRT no
estándar(Posner and Vermonken NEJM
2007)
Ricardo Hitt 7
British Journal of Cancer 2000; 83: 1594-1598
GETTEC, French
318, HNSCC, oropharynx stage II-IV
Induction C/T
Cisplatin 100mg/m2, D1
5-FU 1000mg/m2, D1-D5 q3w, 3 cycles
Operable: Surgery RT
Inoperable: RT
Operable: Surgery RT
Inoperable: RT
Ricardo Hitt 8
chemotherapy
No chemotherapy
Overall survival p=0.03
chemotherapy
No chemotherapy
Dz-free survival p=0.11
GETTEC, French
Ricardo Hitt 9
Journal of the National Cancer Institute 1994; 86: 265-272
Journal of the National Cancer Institute 2004; 96: 1714-1717
GSTTC, Italy
237, HNSCC, stage III/IV
Induction C/T Operable: Surgery RT
Inoperable: RT
Cisplatin 100mg/m2, D1
5-FU 1000mg/m2, D1-D5
q3w, 4 cycles
Oral cavity
Oropharynx
Hypopharynx
Para-nasal
sinus
Operable: Surgery RT
Inoperable: RT
A
B
A B
Operable 29% 27%
Inoperable 71% 73%
Ricardo Hitt 10
All pts
Operable group
Inoperable group
Overall survival
Overall survival
Overall survival
Inoperable Operable
A 24% 3%
B 42% 31%
p value 0.04 0.01
3-yr distant metastasis rate
Ricardo Hitt 11
100 pts, HNSCC stage III/IV
RT alone
CCRT
RT: 66-72Gy, conventional, 1.8-2Gy/fx
5yr OS RFS Dist. Mets-
free survival
OS with primary
site preserve
Local control
without resection
RT 48% 51% 75% 34% 45%
CCRT 50% 62% 84% 42% 77%
p value 0.55 0.04 0.09 0.004 <0.001
Oral cavity 4%
Oropharynx 44%
Hypopharynx 16%
Larynx 36%
Aldelstein DJ et al
Cancer 2000; 88: 876-883
Cisplatin: 20mg/m2/d
5FU: 1000mg/m2/d
Infusion, D1-D4 D22-D25
Primary site resection +/- neck dissection
Residual dz or recurrence
Survival benefit from better local control
Ricardo Hitt 12
New England Journal of Medicine 1991; 324: 1685-1690
Veterans Affairs Laryngeal Cancer Study Group
332 pts, laryngeal SCC stage III/IV
Surgery
Surgery +/- RT
C/T x 2
Cisplatin 100mg/m2, D1
5FU 1000mg/m2/d x 5d q3w
RT: 5000cGy/25fx Adjuvant RT
Definitive RT
RT: 6600-7600cGy
C/T x 1
Residual disease Poor
respond
2yr DFS OS Recur at
primary
Recur at
regional
Distant
mets
Laryngectomy-
free survival
Surgery 75% 68% 2% 5% 17%
C/T RT 65% 68% 12% 8% 11% 39%
p value 0.12 0.98 0.001 NS 0.001
T1/T2 9%
T3 65%
T4 26%
Glottis 37%
Supraglottis 63%
Ricardo Hitt 13
Journal of National Cancer Institute 1996; 8: 890-899
EORTC
194 pts, hypopharynx SCC stage II/III/IV
Surgery
Surgery +/- RT
C/T x 2
Cisplatin 100mg/m2, D1
5FU 1000mg/m2/d x 5d q3w
RT: 5000cGy/25fx Adjuvant RT
Definitive RT
RT: 7000cGy
C/T x 1
Residual disease Poor
respond
5yr DFS OS Recur at
local
Recur at
regional
Distant
mets
Laryngectomy-
free survival
Surgery 32% 35% 17% 23% 36%
C/T RT 25% 30% 12% 19% 25% 35%
p value NS NS NS NS 0.041
T2 20%
T3 75%
T4 5%
Pyriform
sinus 78%
Aryepiglottic
fold 22%
Ricardo Hitt 14
New England Journal of Medicine 2003; 349: 2091-2098
RTOG 91-11
518 pts, laryngeal SCC III/IV
Surgery +/- RT
C/T x 2
Cisplatin 100mg/m2, D1
5FU 1000mg/m2/d x 5d
q3w
CCRT
RT
CCRT: RT 7000cGy/35fx Cisplatin 100mg/m2, q3w
C/T x 1 Residual disease
Poor respond
5yr DFS OS Intact
larynx
LR
control
Distant
mets
A: RT 27% 56% 70% 56% 22%
B: CCRT 36% 54% 88% 78% 12%
C: C/TRT 38% 55% 75% 61% 15%
p 0.02(C v A)
0.006(B v A) NS
0.005(B v C)
0.001(B v A)
0.004(B v C)
0.001(B v A) 0.03(B v A)
RT alone
Speech/swallow : similar
T2 12%
T3 78%
T4 10%
Supraglottis 69%
Glottis 31%
Ricardo Hitt 15
UNRESECTABLE SCCHN
Paccagnella JNCI (Nov 2004)
OVERALL SURVIVAL
5 years: CF 23%; control : 19% (ns) 10 years: CF 16% vs 9% (ns)
unresectable
5 years: 21% vs. 16%
10 years: 8% vs. 6%
P= 0.04
Ricardo Hitt 16
Journal of Clinical Oncology 2005; 23: 8636-8645
382 pts, HNSCC stage III/IV
CF x 3
PCF x 3
Hitt R et al, Spain Paclitaxel 175mg/m2, D1
Cisplatin 100mg/m2, D2
5FU 500mg/m2/d, D2-D6
Cisplatin 100mg/m2, D1
5FU 1000mg/m2/d, D1-D5
Oral cavity 13%
Oropharynx 34%
Hypopharynx 23%
Larynx 30%
q3w
q3w
CCRT
Cisplatin 100mg/m2, q3w
RT 7000cGy/35fx
CR or PR>80%
Poor responder
Salvage surgery Resectable 35%
Unresectable 65%
Ricardo Hitt 17
Induction
CR neutropenia mucositis Median
survival
Time to tx
failure
PCF 33% 37% 53% 43m 36m
CF 14% 36% 16% 37m 26m
p value <0.001 <0.001 0.03 0.03
Hitt R et al, Spain
Journal of Clinical Oncology 2005; 23: 8636-8645
Dose density
Cisplatin 5FU Paclitaxel
PCF 91% 98% 99%
CF 81% 91%
p value <0.001 <0.001
Ricardo Hitt 18
Time to Treatment Failure
PF (n= 193), 112 Events
PFT (n= 190), 93 Events
Log-rank, p=0.024
PF (median)= 17.7 (11.4 - 23.9) PFT (median)= 21.7 (14.9 - 28.4)
Ricardo Hitt 19
20
Final results of a randomized Phase III trial
comparing induction chemotherapy (ICT)
with cisplatin/5-FU (PF) or
docetaxel/cisplatin/5-FU (TPF) followed by
chemoradiotherapy (CRT) versus CRT
alone as first-line treatment of
unresectable locally advanced head and
neck cancer (LAHNC)
SPANISH HEAD AND NECK CANCER
GROUP
Hitt et.al ASCO 2009
BEST OF ASCO . Annals
of Oncology (in press)
Ricardo Hitt 20
Safety: Adverse events
21
Grade 3/4 AEs,
% patients
CRT
(N=118)
PF plus
CRT
(N=156)
TPF plus
CRT
(N=153)
Total ICT
(TPF + PF)
(N=309)
Neutropenia 20 38 34 36
Febrile neutropenia 1 3 19 11
Thrombocytopenia 4 10 10 10
Asthenia 3 9 14 11
Mucositis 32 43 41 42
Radiation Dermatitis 4 2 0 1
Ricardo Hitt 21
22
p=0.016
% patients
CRT (N=119)
Combined ICT + CRT (N=234)
51.7
65
Por protocolo
Secondary endpoint: LCR
Ricardo Hitt 22
ICT + CRT
CRT
CRT; median 13.3months
HR=0.747;95% CI 0.575-0.971 P=0.0294
ICT + CRT; median 18.2 months
ICT + CRT
CRT
(months)
Tiempo libre de evento
Ricardo Hitt 23
POR PROTOCOLO
Fracaso al tratamiento
CRT ICT + CRT
ICT + CRT; median 14.4 months
CRT; median 6.1 months
HR=0.646;95% CI 0.501-0.835 P= <0.001
CRT
ICT + CRT
Ricardo Hitt 24
POR PROTOCOLO
Tiempo libre de evento
(months)
CRT
ICT + CRT
CRT; median 13.8 months
Log-Rank p=0.426
ICT + CRT; median 14.3 months
CRT
ICT + CRT
Ricardo Hitt 25
INTENCIÓN DE TRATAR
CRT
ICT + CRT
CRT
ICT + CRT
CRT; median 7.1 months
Log-Rank p=0.3259
ICT + CRT; median 8.9 months
(months)
Ricardo Hitt 26
Fracaso al tratamiento INTENCIÓN DE TRATAR
Head and Neck Cancer
Pretreatment considerations
Comorbid chronic diseases
• Pulmonary
• Cardiovascular
• Digestive
Malnutrition
• Resulting from poor dietary habits or symptoms
• Severe in over 25% of patients
Oral health
• Periodontal disease, infections, and caries common
• Dental rehabilitation indicated prior to radiotherapy
Schantz SP, et al. Cancer: Principles & Practice of Oncology. 6th ed. 2001;797-860.
Ricardo Hitt 27
CRT: Significant increase in
acute toxicity
Acute adverse effects: Grade ≥3
p<0.05
ns
p<0.01
Wendt TG, et al. J Clin Oncol 1998;16:1318–1324
0 10 20 30 40 50 60
Xerostomia
Nausea/emesis
Leukopenia
Dermatitis
Mucositis
RT alone (n=140)
CRT (n=130)
Ricardo Hitt 28
CRT: Late toxicity
• Analysis of 230 patients receiving CRT in 3 studies (RTOG 91-11, 97-03, 99-14)
• Factors associated with development of severe late toxicitya o Older age (p=0.001), advanced T-stage (p=0.0036), larynx/hypopharynx
primary (p=0.004), neck dissection after RT (p=0.018)
10% 12%
27%
13%
43%
0
10
20
30
40
50
Pat
ien
ts (
%)
Any severe
late toxicity
Feeding tube
dependence
>2 yrs post-RT
Pharyngeal
dysfunction
Laryngeal
dysfunction DeatH
a Chronic grade 3-4 pharyngeal/laryngeal toxicity and/or requirement for feeding tube >2 years after registration and/or
potential treatment-related death within 3 years
Machtay M, et al. J Clin Oncol 2008;26: 3582-3589 29 Ricardo Hitt
TREMPLIN study: Organ preservation with
Erbitux + RT after induction TPF
Lefebvre J, et al. J Clin Oncol 2013;31:853–859
71% could receive the full Erbitux protocol
43% could receive the full cisplatin protocol
Previously untreated SCC larynx/hypopharynx
Suitable for total laryngectomy
Erbitux
R ≥PR
Total laryngectomy +
postoperative RT
TPF
(3 cycles, q3w)
(n=153)
RT (70 Gy)
<PR
56 pts
60 pts
116 (76%) pts
q3w: every 3 weeks; R: randomized
Primary endpoint: larynx preservation 3 months post treatment Secondary endpoints: Preservation of larynx function 18 months after end of treatment, OS, tolerance to and compliance with treatment, feasibility of salvage surgery
Cisplatin
RT (70 Gy)
Ricardo Hitt 31
TREMPLIN study: High rate of protocol
modification due to acute toxicity with Chemo + RT
Lefebvre J, et al. J Clin Oncol 2013;31:853–859
Cisplatin + RT n=58* (%)
Erbitux + RT n=56 (%)
Protocol modification due to acute toxicity
33 (57.0) 19 (33.9)
Grade 3–4 mucositis 27 (46.6) 25 (44.6)
Grade 3–4 in-field skin toxicity 15 (25.9) 32 (57.1)
Grade 3–4 laryngoesophageal toxicity 5 (8.6) 5 (8.9)
Renal toxicity (any grade) 9 (15.5) 0 (0.0)
* 2 patients did not start treatment in the cisplatin arm
Ricardo Hitt 32
TREMPLIN study: Erbitux preserves organ
function in locally advanced SCCHN
Lefebvre J, et al. J Clin Oncol 2013;31:853–859
*3 months after end of treatment
**18 months after end of treatment
For patients who were randomized (n=116 [76%])
Primary
endpoint*
● Chemo + RT is associated with acute and long-term toxicity
● Erbitux + RT shows a manageable, well-tolerated profile
Erbitux + RT Chemo + RT
Secondary
endpoints** 92
87
95
89
82
93
0 20 40 60 80 100
Overall
survival
Larynx function
preservation
Larynx
preservation
Patients (%)
Ricardo Hitt 33
TREMPLIN study: Overall survival (ITT)
Lefebvre J, et al. J Clin Oncol 2013;31:853–859
100
80
60
40
20
0
Overa
ll surv
ival in
%
Patients at risk Chemo + RT 60 56 (0.93) 51 (0.84) 32 (0.78) 13 (0.70)
Erbitux + RT 56 52 (0.93) 45 (0.82) 25 (0.71) 11 (0.71)
Months
Up to 18 months HR: 0.98 (95% CI: 0.26, 3.66), log-rank: p=0.68
Up to 36 months HR: 0.84 (95% CI: 0.34, 2.08), log-rank: p=0.50
Erbitux + RT
Chemo + RT
0 12 24 36 48 60
ITT: intent to treat
Ricardo Hitt 34
TREMPLIN study:
Pronounced late toxicity profile for Chemo + RT
Lefebvre J, et al. J Clin Oncol 2013;31:853–859
Cisplatin n=58* (%)
Erbitux n=56 (%)
Residual renal dysfunction at last evaluation (all grade 1)
13 (22.4) 0 (0.0)
4 cycles 5 cycles 6 cycles
3% 5%
14%
Grade 3/4 mucosal toxicity 2 (3.5) 1 (1.8)
Grade 3/4 osteoradionecrosis 1 (1.7) 1 (1.8)
Grade 3/4 xerostomia 6 (10.3) 5 (8.9)
Grade 3/4 subcutaneous fibrosis 4 (7.0) 1 (2.0)
Grade 3/4 neuropathy 2 (3.4) 0 (0.0)
*2 patients did not start treatment in the cisplatin arm
Ricardo Hitt 35
DISEÑO ENSAYOS
CLINICOS
• META ANÁLISIS : Datos Concluyentes
• Taxane-Cisplatin-Fluorouracil As Induction Chemotherapy in Locally Advanced Head and Neck Cancers: An Individual Patient Data Meta-Analysis of the Meta-Analysis of Chemotherapy in Head and Neck Cancer Group
• Pierre Blanchard, Jean Bourhis, Benjamin Lacas, Marshall R. Posner, Jan B. Vermorken, Juan J. Cruz Hernandez, Abderrahmane Bourredjem, Gilles Calais, Adriano Paccagnella, Ricardo Hitt, and Jean-Pierre Pignon , on behalf of the Meta-Analysis of Chemotherapy in Head and Neck Cancer, Induction Project, Collaborative Group
• JCO Aug 10, 2013:2854-2860; DOI:10.1200/JCO.2012.47.7802.
Ricardo Hitt 35
Survival curves for (A) overall survival, (B) progression-
free survival, (C) locoregional failure, and (D) distant
failure.
Blanchard P et al. JCO 2013;31:2854-2860
Ricardo Hitt 36
ROLE OF PRIMARY
CHEMOTHERAPY Neoplasms in which Chemotherapy is the Primary Therapeutic Modality for Localized Tumors
-Large cell lynphoma
-Lymphoblastic lymphoma
-Wilms’ tumor
-Embryonal rhabdomyosarcoma
-Small cell lung cancer?
-Central nervous system lymphoma
DeVita 2004
Ricardo Hitt 37
ROLE OF PRIMARY
CHEMOTHERAPY
Neoplasms in which Primary Chemotherapy Can Allow Less Mutilating Surgery:
-Anal carcinoma
-Bladder carcinoma
-Breast cancer
-Laryngeal cancer -Osteogenic sarcoma
-Soft tissue sarcoma
Ricardo Hitt 38
ROLE OF PRIMARY
CHEMOTHERAPY
Neoplasms in which Clinical Trials Indicate an Expanding Role for Primary Chemotherapy in the Future
-Non-small cell lung cancer
-Bladder cancer
-Cervical cancer
-Gastric cancer
-Head and Neck Cancer -Pancreas cancer
-Prostate cancer
Ricardo Hitt 39
CONCLUSIONES La quimioterapia de inducción en tumores de cabeza y cuello tras 20 años de desarrollo ha demostrado: PERMITIR PRESERVACIÓN DE ÓRGANOS MEJORÍA DE SUPERVIVENCIA EN TUMORES IRRESECABLES MEJOR CONTROL LOCO-REGIONAL EN TUMORES IRRESECABLES INCREMENTO DE TOXICIDAD CUANDO SE COMBINA CON QTRT SER FACTIBLE SOLO EN POBLACIÓN SELECCIONADA Y CENTROS CON EXPERIENCIA SE PODRÍA PLANTEAR ESQUEMAS MENOS TÓXICOS CON CETUXIMAB EN INDUCCIÓN?
Ricardo Hitt 40